Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Director/PDMR Shareholding

3 Nov 2020 14:54

RNS Number : 1387E
Angle PLC
03 November 2020
 

ANGLE plc

("ANGLE" or "the Company")

 

Director/PDMR Dealings

 

 

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, has been notified that the following Directors of the Company purchased ordinary shares of 10 pence each in the Company ("Ordinary Shares") on 2 November 2020:

 

- Ian Griffiths, Finance Director of the Company, purchased 30,000 Ordinary Shares at a price of 44.75 pence per Ordinary Share. Following this purchase Mr. Griffiths is beneficially interested in a total of 703,832 Ordinary Shares, representing approximately 0.41 per cent of the Company's currently issued share capital; and

 

- Garth Selvey, Non-Executive Chairman of the Company, purchased 30,000 Ordinary Shares at a price of 45.00 pence per Ordinary Share. Following this purchase Mr. Selvey is beneficially interested in a total of 50,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's currently issued share capital.

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information ANGLE:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley

ECM - Alice Lane, Sunila de Silva

 

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 

+44 (0) 203 705 9330

 

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

+44 (0) 203 727 1000

+1 212 850 5624

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Ian Griffiths

2

Reason for the notification

 

 

a)

Position/status

 

 

Finance Director

b) 

Initial notification /Amendment

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

44.75p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 44.75p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Garth Selvey

2

Reason for the notification

 

 

a)

Position/status 

 

 

Non-Executive Chairman

b) 

Initial notification /Amendment 

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name 

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

45.00p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 45.00p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFBBFLEFBX
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.